Susceptibility of human T cell leukemia virus type I to nucleoside reverse transcriptase inhibitors.
A single-cycle infection assay with recombinant viral vectors was developed to study human T cell leukemia virus type I (HTLV-I) replication and its inhibition by antiviral agents. The susceptibility of HTLV-I to 6 nucleoside reverse-transcriptase inhibitors was examined. HTLV-I replication was inhibited by tenofovir, abacavir, lamivudine, zalcitabine, stavudine, and zidovudine.
Hill
Shawn A
SA
Basic Research Laboratory, Center for Cancer Research, Frederick, Maryland, USA.
Lloyd
Patricia A
PA
McDonald
Shannon
S
Wykoff
Jennifer
J
Derse
David
D
D000225:Adenine / Q000031:analogs & derivatives* / Q000494:pharmacology; D002460:Cell Line; D015224:Dideoxynucleosides / Q000494:pharmacology; D015368:Human T-lymphotropic virus 1 / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D019259:Lamivudine / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000494:pharmacology; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology*; D018119:Stavudine / Q000494:pharmacology; D000068698:Tenofovir; D014779:Virus Replication / Q000187:drug effects; D016047:Zalcitabine / Q000494:pharmacology; D015215:Zidovudine / Q000494:pharmacology; D000099227:Abacavir
D000225:Adenine; D015224:Dideoxynucleosides; D019259:Lamivudine; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D018894:Reverse Transcriptase Inhibitors; D018119:Stavudine; D000068698:Tenofovir; D016047:Zalcitabine; D015215:Zidovudine; D000099227:Abacavir